Solid Biosciences SLDB
NASDAQ SLDB
$6.47 +0.07 (+1.17%)
As of: Oct 21, 2026 · 11:41 AM EDT

Solid Biosciences (SLDB) Receivables (2021)

Updated

Solid Biosciences' Receivables came in at $220,000 for Q4 2021.

Analysis

Solid Biosciences (SLDB) Receivables (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn 19.05 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn 13.82 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 15.68 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn 5.06 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn 12.49 Bn
10 Solid Biosciences 931.82 Mn -250.53 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 220,000.00
API Access

Solid Biosciences Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=SLDB&period=max&api_key=YOUR_API_KEY